|A community-of-interest newsletter for Dialog customers|
Recent Dialog Pharmaceutical Forums held in numerous locations presented sessions on how to get the most from the pharmaceutical databases on Dialog and DataStar. Attendees were very interested in pharmacovigilance and chemical structure searching in the Dialog pipeline databases, two of the topics covered in the Forums. More Pharmaceutical Forums are planned for 2007. Dates and locations will be announced in an upcoming issue of Pharma/Biotech News.
In this issue we highlight some of the changes in the Adis and IMS drug pipeline files. See how new fields added to the databases will allow you to structure your searches and Alerts more specifically and gain the latest information about ongoing clinical trials.
Bonnie Snow, Director
Adis Clinical Trails Insight (File 173, 373/ACTI) has been reloaded with new fields to let you pinpoint exactly the information you need and track the latest developments in ongoing clinical trials. New fields in the file include: Drug Name, References, ATC WHO Codes, EphMRA codes, creation date, study identifiers, Adis R&D Insight (File 107/ADRD) links, meeting name, study name, patient minimum and maximum age/units, planned number of patients, Study status, Latest update date.
Comprehensive Information about Ongoing Trials
IMS R&D Focus (IPUR) on DataStar has been reloaded resulting in more content and improved functionality. Additional data enable you to identify important concepts in drug research such as:
New fields enable you to set up your Alert strategies to focus specifically on areas like document and development phase changes or route of administration.
Publisher records are now available in MEDLINE (MEDL, MEZZ, MEIP) on DataStar. There are several differences between these records and those in MEDLINE:
Publisher records are handled in the same way as other “In Process” records and will be overwritten when they appear in MEDLINE later. You can retrieve Publisher records on DataStar with PUBLISHER=YES or PUBLISHER.AN. and identify them by the presence of the word “Publisher” in the Accession Number field.
For a comprehensive understanding of the current drug research environment, it is vital to consult multiple databases. A study by Diane Q. Webb and John A. Willmore of BizInt Solutions Inc. shows that searching only one pipeline database will generally retrieve only about 40 percent of the unique compounds in the pipelines of all drug companies.
Read the article by Bob Stewart, entitled "Comprehensive Drug Monitoring Through Multi-File Chemical Structure Searching," to learn more about this important topic.
In his article, Stewart illustrates that only by
searching multiple pipelines and using chemical structure
searching can researchers be truly assured of a comprehensive
search, thereby protecting investments made in current